Search Results

You are looking at 161 - 170 of 848 items for :

  • Refine by Access: All x
Clear All
Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed

Full access

Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?

Presented by: Shaji K. Kumar

Therapeutic advances have led to prolonged survival in multiple myeloma (MM), but it remains a chronic disease. The addition of several new therapies for both newly diagnosed and relapsed disease has also added complexity to treatment algorithms

Full access

Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers

Presented by: Lihua E. Budde, Stacy Pak, and Lauren R. Seipel

based on results from the phase III TOWER trial, in which patients with relapsed/refractory ALL were randomly assigned to receive blinatumomab or standard-of-care chemotherapy. With the primary endpoint of overall survival, the median duration was 7

Full access

Acute Lymphoblastic Leukemia

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory

independent predictors for risk of relapse or death; the prognostic impact of these cytogenetic markers was independent of factors such as age, WBC count, or T-cell immunophenotype, and their significance was retained even after excluding patients who had

Full access

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Jonathan Brammer, Mark W. Clemens, Ahmet Dogan, Francine Foss, Paola Ghione, Aaron M. Goodman, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Avyakta Kallam, Youn H. Kim, Kiran Kumar, Neha Mehta-Shah, Elise A. Olsen, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Lauren Shea, Michi M. Shinohara, Lubomir Sokol, Carlos Torres-Cabala, Ryan Wilcox, Peggy Wu, Jasmine Zain, Mary Dwyer, and Hema Sundar

POD24 in patients with newly diagnosed PTCL was also demonstrated in subsequent studies. 30 , 36 – 38 These results suggest that patients with primary refractory disease or early relapse have extremely poor survival and that POD24 could be used for

Full access

Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Matthew Barth, Ana C. Xavier, Saro Armenian, Anthony N. Audino, Lindsay Blazin, David Bloom, Jong Chung, Kimberly Davies, Hilda Ding, James B. Ford, Paul J. Galardy, Rabi Hanna, Robert Hayashi, Cathy Lee-Miller, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Paul L. Martin, David McCall, Martha Pacheco, Anne F. Reilly, Mikhail Roshal, Sophie Song, Joanna Weinstein, Sara Zarnegar-Lumley, Nicole McMillian, Ryan Schonfeld, and Hema Sundar

be considered for patients experiencing less than CR (positive PET; Deauville 4–5). Patients experiencing less than CR to initial treatment should be managed as described for relapsed/refractory disease. Biopsy of PET-positive mass is recommended if

Full access

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M. Boughan, Bouthaina Dabaja, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Alex F. Herrera, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Matthew McKinney, Monika Metzger, David Morgan, Carolyn Mulroney, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

ABVD ( P <.001). The 5-year PFS rate was 95.4% and 89.1%, respectively ( P <.001). 73 The 5-year OS rate was not significantly different between the 2 arms (97.2% and 96.8%, respectively; P =.731). The rate of progression or relapse was also lower in

Full access

Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia

Hany Elmariah and Keith W. Pratz

prevent relapse. 1 In patients at high risk of relapse due to advanced age, unfavorable cytogenetics or molecular mutations, AML secondary to an antecedent hematologic malignancy, or relapsed/refractory disease, an allogeneic hematopoietic cell transplant

Full access

Supportive Therapies in Multiple Myeloma

Charise Gleason, Ajay Nooka, and Sagar Lonial

Sonneveld P Schuster MW . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma . N Engl J Med 2005 ; 352 : 2487 – 2498 . 6 Richardson PG Sonneveld P Schuster MW . Reversibility of symptomatic peripheral neuropathy with